Early-stage biotech investing offers significant growth potential, demanding a thorough evaluation of scientific innovation, market opportunity, and management strength to achieve 200% returns within three years.

This article explores the landscape of undervalued US biotech stocks, identifying companies with promising pipelines and market positions poised for over 15% growth by Q3 2025, offering strategic insights for investors.